Form 8-K - Current report:
SEC Accession No. 0001493152-22-010016
Filing Date
2022-04-15
Accepted
2022-04-15 09:52:46
Documents
12
Period of Report
2022-04-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38280
  Complete submission text file 0001493152-22-010016.txt   212242

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anix-20220414.xsd EX-101.SCH 3024
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anix-20220414_lab.xml EX-101.LAB 34476
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anix-20220414_pre.xml EX-101.PRE 22589
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3623
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 22829205
SIC: 2834 Pharmaceutical Preparations